Sprint Bioscience (SPRINT) Q4 2025 earnings summary

Executive summary

• Achieved a transformative year with strengthened financial position and strategic focus, highlighted by the sale of the TREX1 cancer program to Gilead Sciences for $14 million upfront and potential milestones up to $400 million.

• Undertook portfolio reprioritization, including staff reductions and program discontinuations, to focus on high-potential projects and cost discipline.

• Expanded scientific and commercial partnerships, with positive preclinical data and new collaborations in inflammation and oncology.

Financial highlights

• Net revenue for the year was 167.2 MSEK, up from 65.6 MSEK year-over-year; Q4 revenue was 133.9 MSEK, up from 16.3 MSEK.

• Operating income for the year reached 97.3 MSEK (previous year: -19.7 MSEK); Q4 operating income was 117.5 MSEK (previous year: -4.9 MSEK).

• Net income for the year was 91.7 MSEK (previous year: -18.3 MSEK); Q4 net income was 113.2 MSEK (previous year: -4.2 MSEK).

• Earnings per share for the year were 0.99/0.98 SEK (previous year: -0.26 SEK); Q4 EPS was 1.07/1.06 SEK (previous year: -0.06 SEK).

• Cash flow from operations for the year was 83.5 MSEK (previous year: -23.4 MSEK); cash at year-end was 126.7 MSEK (previous year: 25.1 MSEK).

Outlook and guidance

• Entering 2026 with a strong cash position, focused portfolio, and a clear agenda to drive licensing and partnerships for key programs.

• No formal financial forecast provided.